

**SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

FibroBiologics, Inc.

(Name of Issuer)

Common Stock, \$0.00001 par value

(Title of Class of Securities)

31573L204

(CUSIP Number)

04/02/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

SCHEDULE 13G

CUSIP 31573L204
Number(s):

1	Names of Reporting Persons Lind Global Fund III LP
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 230,234.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 230,234.00
	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 230,234.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>	
11	Percent of class represented by amount in row (9) 4.99 %	
12	Type of Reporting Person (See Instructions) PN	

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate.

(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 31573L204

1	Names of Reporting Persons Lind Global Partners III LLC	
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 230,234.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 230,234.00
	8	Shared Dispositive Power 0.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 230,234.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 4.99 %
12	Type of Reporting Person (See Instructions) CO

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate.

(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

CUSIP Number(s): 31573L204

1	Names of Reporting Persons EASTON JEFF
2	Check the appropriate box if a member of a Group (see instructions) <input type="checkbox"/> (a) <input checked="" type="checkbox"/> (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES
Number of Shares Beneficially Owned by Each Reporting Person With:	5 Sole Voting Power 230,234.00
	6 Shared Voting Power 0.00
	7 Sole Dispositive Power 230,234.00
	8 Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 230,234.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) <input type="checkbox"/>
11	Percent of class represented by amount in row (9) 4.99 %
12	Type of Reporting Person (See Instructions) IN

Comment for Type of Reporting Person: (1) The reporting person's ownership consists of (i) 157,956 shares of common stock and (ii) 540,536 warrants to purchase shares of common stock (the "Warrants"); however, due to the conversion limitations on the Warrants, the reporting person's beneficial ownership has been limited to 230,234 shares in the aggregate.

(2) The Warrants include a provision limiting the holder's ability to convert the Warrants if such conversion would cause the holder to beneficially own greater than 4.99% of the Company.

SCHEDULE 13G

Item 1.

(a) **Name of issuer:**

FibroBiologics, Inc.

(b) **Address of issuer's principal executive offices:**

55 E. Medical Center Blvd, Suite 300, Houston, Texas, 77598

Item 2.

(a) **Name of person filing:**

This statement is filed by the following entities and individuals (collectively, referred to as the "Reporting Persons"):

- o Lind Global Fund III LP, a Delaware limited partnership;
- o Lind Global Partners III LLC, a Delaware limited liability company; and
- o Jeff Easton, an individual and a citizen of the United States of America.

Lind Global Partners III LLC, the general partner of Lind Global Fund III LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.

Jeff Easton, the managing member of Lind Global Partners III LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund III LP.

(b) **Address or principal business office or, if none, residence:**

The address of the principal business office for each of the Reporting Persons is:

444 Madison Ave, Floor 41
New York, NY 10022

(c) **Citizenship:**

See Row 4 of cover page for each Reporting Person.

(d) **Title of class of securities:**

Common Stock, \$0.00001 par value

(e) **CUSIP Number(s):**

31573L204

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
- (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
- (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
- (j) A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) **Amount beneficially owned:**

See Row 9 of cover page for each Reporting Person.

(b) **Percent of class:**

See Row 11 of cover page for each Reporting Person.

(c) **Number of shares as to which the person has:**

(i) **Sole power to vote or to direct the vote:**

See Row 5 of cover page for each Reporting Person.

(ii) **Shared power to vote or to direct the vote:**

See Row 6 of cover page for each Reporting Person.

(iii) **Sole power to dispose or to direct the disposition of:**

See Row 7 of cover page for each Reporting Person.

(iv) **Shared power to dispose or to direct the disposition of:**

See Row 8 of cover page for each Reporting Person.

Item 5. Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

Not Applicable

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Lind Global Fund III LP

Signature: By: Lind Global Partners III LLC, its General Partner, By: /s/ Jeff Easton

Name/Title: Jeff Easton, Managing Member

Date: 04/09/2026

Lind Global Partners III LLC

Signature: /s/ Jeff Easton
Name/Title: Jeff Easton, Managing Member
Date: 04/09/2026

EASTON JEFF

Signature: /s/ Jeff Easton
Name/Title: Jeff Easton
Date: 04/09/2026

Exhibit Information

99.1 Joint Filing Agreement by and among the Reporting Persons.

JOINT FILING AGREEMENT

The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, \$0.00001 par value, of FibroBiologics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.

April 9, 2026

LIND GLOBAL FUND III LP

By: Lind Global Partners III LLC
its General Partner

By: /s/ Jeff Easton
Name: Jeff Easton
Title: Managing Member

LIND GLOBAL PARTNERS III LLC

By: /s/ Jeff Easton
Name: Jeff Easton
Title: Managing Member

JEFF EASTON

By: /s/ Jeff Easton